Nanoplasmid Platform

NanoplasmidTM Platform for Genetic Payload Optimization

The Nanoplasmid Platform provides significant advantages over existing legacy plasmid DNA backbones and selection methods. Combining characteristics of reduced size and non-antibiotic resistance, the platform is ideally suited for gene therapy applications. 
 
Using Nanoplasmid technology licensed from Nature Technology Corporation, Aldevron provides plasmid DNA customized for each client. For applications where the Nanoplasmid is not the API or in the final product (for example, when used as a raw material in viral vector production or when used as a transposon or transposase raw material to create genetically modified CAR-T cells), clients do not need to pay any royalties or license fees beyond the purchase price of the product.*
Nanoplasmid

*The Nanoplasmid Platform is available royalty-free when not used as a direct gene transfer vector (plasmid vector that is in the final clinical product).  Use of the Nanoplasmid Platform as a direct gene transfer vector requires a license from Nature Technology Corporation.

 

Nanoplasmid Platform advantages

The Nanoplasmid Platform provides several advantages for use as a genetic cargo delivery system.

  • Small bacterial region size (< 500 bp)
  • Improved manufacturing yields, lower cost
  • Reduced toxicity and silencing
  • High transgene expression
  • Free of antibiotic markers, no residual antibiotics

Nanoplasmids for viral vector production

In addition to the overall advantages of the Nanoplasmid Platform, the system has features uniquely suited to AAV vector production.  Studies have shown that when bacterial sequences are removed during production, as is the case with the Nanoplasmids, "encapsidation of prokaryotic backbone sequences is avoided."1  In addition, the studies showed that transduction efficiency of self-complementary AAV preparations improved up to 30-fold.  The Nanoplasmid Platform combined with standard AAV packaging protocols can significantly improve the quality of AAV vectors.

1 Schnödt, M. et al. DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations. Mol Ther - Nucleic Acids 5, e355 (2016).

Nanoplasmid RNA-OUT for any plasmid

The Nanoplasmid Platform is flexible and any plasmid can be modified to use the antibiotic-free selection method.  We can design and synthesize your plasmid for any gene therapy application.

Nanoplasmid Vectors

* The Nanoplasmid Platform is available royalty-free when not used as a direct gene transfer vector (plasmid vector that is in the final clinical product).  Use of the Nanoplasmid Platform as a direct gene transfer vector requires a license from Nature Technology Corporation.

Contact us for more information on Nanoplasmids